Sphingolipids as prognostic biomarkers of neurodegeneration, neuroinflammation, and psychiatric diseases and their emerging role in lipidomic investigation methods
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Lipids play an important role in neurodegeneration, neuroinflammation, and psychiatric disorders and an imbalance in sphingolipid levels is associated with disease. Although early diagnosis and intervention of these disorders would clearly have favorable long-term outcomes, no diagnostic tests currently exist that can accurately identify people at risk. Reliable prognostic biomarkers that are easily accessible would be beneficial to determine therapy and treatment response in clinical trials. Recent advances in lipidomic investigation methods have greatly progressed the knowledge of sphingolipids in neurodegenerative and psychiatric disorders over the past decades although more longitudinal studies are needed to understand its exact role in these disorders to be used as potential tools in the clinic. In this review, we give an overview of the current knowledge of sphingolipids in neurodegenerative and psychiatric disorders and explore recent advances in investigation methods. Finally, the potential of sphingolipid metabolism products and signaling molecules as potential biomarkers for diagnosis, prognostic, or surrogate markers of treatment response is discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Parkinson's disease: clinical features and diagnosis
Jankovic, J. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.131045 · Cited by 5,720
Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901281 · Cited by 2,135 · cited 1×
“Glucocerebrosidase (GBA, the enzyme breaking down GlcCer into glucose and ceramide) has been implicated in sporadic PD and Lewy Body Dementia since mutations in the gene coding for this enzyme is one of the most established genetic risk factors for these diseases [104].”
BackgroundFunctional organization of the hippocampal longitudinal axis
Strange, B. A., Witter, M. P., Lein, E. S., & Moser, E. I. (2014) · Nature reviews. Neuroscience · doi:10.1038/nrn3785 · Cited by 1,738 · cited 3×
“Another study observed a relative increase in ceramide dorsal to ventral hippocampal levels in a relearning extinction paradigm [187], which overall, further supports that the subregional hippocampal lipid composition can be a key contributor to stress susceptibility, potentially affecting circuits predominantly invol…”
BackgroundKappos, L., Bar-Or, A., Cree, B. A. C., Fox, R. J., Giovannoni, G., Gold, R., Vermersch, P., Arnold, D. L., Arnould, S., Scherz, T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30475-6 · Cited by 942 · cited 1×
“After a successful phase 3 trial, termed the “EXPAND” study, where siponimod was tested against placebo in secondary progressive MS [161], FDA approval was given in 2019, making it the first oral drug treatment for secondary progressive MS with active disease [166].”
MethodLipid composition of the normal human brain: gray matter, white matter, and myelin
O'Brien, J. S., & Sampson, E. L. (1965) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39619-x · Cited by 848
Comparative Lipidomic Analysis of Mouse and Human Brain with Alzheimer Disease
Chan, R. B., Oliveira, T. G., Cortes, E. P., Honig, L. S., Duff, K. E., Small, S. A., Wenk, M. R., Shui, G., & Di Paolo, G. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.274142 · Cited by 630 · cited 1×
“In a lipidomic analysis where human late-onset AD brain tissue was compared to transgenic familial-AD (FAD) mouse-models with mutations in presenilin 1 (PS1) and APP genes, the authors show that, although many lipid alterations were different between the two models, ganglioside (GM3) and cholesterol esters (CE; compon…”
BackgroundSelf-citationHan, X., M. Holtzman, D., W. McKeel, D., Kelley, J., & Morris, J. C. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00997.x · Cited by 626 · cited 1×
“Additionally, ceramide species are elevated in CSF and brain white matter, which especially peaks in very mild forms of AD dementia [70,71].”
BackgroundDeregulation of sphingolipid metabolism in Alzheimer’s disease
He, X., Huang, Y., Li, B., Gong, C.-X., & Schuchman, E. H. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.05.010 · Cited by 516
Epidemiology of multiple sclerosis
Leray, E., Moreau, T., Fromont, A., & Edan, G. (2016) · Revue Neurologique · doi:10.1016/j.neurol.2015.10.006 · Cited by 478 · cited 1×
“It is estimated to affect one in 1000 North American and European inhabitants, with a markedly greater prevalence in women [142].”
Background
Cited by
Brain lipidomics: From functional landscape to clinical significance
Yoon, J. H., Seo, Y., Jo, Y. S., Lee, S., Cho, E., Cazenave-Gassiot, A., Shin, Y.-S., Moon, M. H., An, H. J., Wenk, M. R., et al. (2022) · Science Advances · doi:10.1126/sciadv.adc9317 · Cited by 324
Acute ischemia induces spatially and transcriptionally distinct microglial subclusters
Li, H., Liu, P., Zhang, B., Yuan, Z., Guo, M., Zou, X., Qian, Y., Deng, S., Zhu, L., Cao, X., et al. (2023) · Genome Medicine · doi:10.1186/s13073-023-01257-5 · Cited by 129
Multiomics Implicate Gut Microbiota in Altered Lipid and Energy Metabolism in Parkinson’s Disease
Pereira, P. A. B., Trivedi, D. K., Silverman, J., Duru, I. C., Paulin, L., Auvinen, P., & Scheperjans, F. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00300-3 · Cited by 40
Song, M., Liu, Y., Zhou, J., Shi, H., Su, X., Shao, M., Yang, Y., Wang, X., Zhao, J., Guo, D., et al. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115070 · Cited by 32
Multiplatform Lipid Analysis of the Brain of Aging Mice by Mass Spectrometry
Panda, P., Ferreira, C. R., Cooper, B. R., Schaser, A. J., & Aryal, U. K. (2025) · Journal of Proteome Research · doi:10.1021/acs.jproteome.4c00688 · Cited by 19
Multiplatform lipid analysis of the brain of aging mice by mass spectrometry
(2024) · doi:10.1101/2024.09.25.614823 · Cited by 19
Metadata
- Authors
- van Kruining, D., Luo, Q., van Echten-Deckert, G., Mielke, M. M., Bowman, A., Ellis, S., Oliveira, T. G., & Martinez-Martinez, P.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2020
- Volume
- 159
- Pages
- 232-244
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W3022486925
- Cited by
- 135
- References
- 25
- FWCI
- 1.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.